164013-29-0

Upstream product

• 258334-04-2 5-((E)-2-Bromo-vinyl)-1-((1S,7R)-4,4-diphenyl-3,5-dioxa-bicyclo[5.1.0]oct-1-ylmethyl)-1H-pyrimidine-2,4-dione 
• 144985-81-9 ethyl (1R,2R)-1,2-bis(hydroxymethyl)-1-cyclopropanecarboxylate 
• 69304-49-0 (E)-5-(2-bromovinyl)uracil 
• 164199-49-9 ethyl (1R,7R)-3,5-dioxa-4,4-diphenylbicyclo[5.1.0]octane-1-carboxylate 
• 164199-50-2 (1S,7R)-3,5-dioxa-4,4-diphenylbicyclo[5.1.0]octane-1-methanol 
• 164199-51-3 (1R,7R)-1-bromomethyl-3,5-dioxa-4,4-diphenylbicyclo[5.1.0]octane 

Relevant academic research and scientific papers

Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety

A series of 5-substituted uracil nucleoside derivatives with a 1(1'S,2'R)-[1',2'-bis(hydroxymethyl)cyclopropyl]methyl group as an acyclosugar moiety were synthesized and evaluated for their anti-herpetic activities. Among the compounds synthesized, (E)-5-

Cyclopropane derivatives and anti-viral agent containing the same

The present invention provides a pharmaceutical agent having a high pharmaceutical potency against varicella-zoster viruses and herpes simplex viruses, compositions containing the same, and methods for treating varicella-zoster viruses using the same.